➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Mallinckrodt
Express Scripts
McKesson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,861,607


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,861,607
Title:Methods of using low-dose doxepin for the improvement of sleep
Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
Inventor(s): Rogowski; Roberta L. (Rancho Santa Fe, CA), Dube; Susan E. (Carlsbad, CA), Jochelson; Philip (San Diego, CA), Kavey; Neil B. (Chappaqua, NY)
Assignee: Procom One, Inc. (San Marcos, TX) Pernix Sleep, Inc. (Morristown, NJ)
Application Number:15/344,710
Patent Claims: 1. A method for treating insomnia characterized by difficulties with sleep maintenance, the method comprising: administering a dosage of doxepin or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences fragmented sleep during the final 60 minutes of said period, wherein the dosage of doxepin is between about 1 and about 6 mg and is administered prior to the start of the sleep period.

2. The method of claim 1, wherein the dosage is effective to improve the insomnia while minimizing next day residual sedation.

3. The method of claim 1, wherein the insomnia is a chronic insomnia.

4. The method of claim 1, wherein the insomnia is a non-chronic insomnia.

5. The method of claim 1, wherein the insomnia is a transient insomnia.

6. The method of claim 1, wherein the patient experiences a sleep period that terminates during the final 45 minutes of said period.

7. The method of claim 1, wherein the patient experiences a sleep period that terminates during the final 30 minutes of said period.

8. The method of claim 1, wherein the dosage of doxepin is about 1 mg.

9. The method of claim 1, wherein the dosage of doxepin is about 3 mg.

10. The method of claim 1, wherein the dosage of doxepin is about 6 mg.

11. The method of claim 1, wherein the pharmaceutically acceptable salt is doxepin hydrochloride.

12. A method for treating insomnia characterized by difficulties with sleep maintenance, the method comprising: administering a dosage of doxepin or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences early awakenings during the final 60 minutes of said period, wherein the dosage of doxepin is between about 1 and about 6 mg and is administered prior to the start of the sleep period.

13. The method of claim 12, wherein the dosage is effective to improve the insomnia while minimizing next day residual sedation.

14. The method of claim 12, wherein the insomnia is a chronic insomnia.

15. The method of claim 12, wherein the insomnia is a non-chronic insomnia.

16. The method of claim 12, wherein the insomnia is a transient insomnia.

17. The method of claim 12, wherein the dosage of doxepin is about 1 mg.

18. The method of claim 12, wherein the dosage of doxepin is about 3 mg.

19. The method of claim 12, wherein the dosage of doxepin is about 6 mg.

20. The method of claim 12, wherein the pharmaceutically acceptable salt is doxepin hydrochloride.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Boehringer Ingelheim
McKesson
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.